Evaluating Rivastigmine in Mild-to-Moderate Parkinson’s Disease Dementia Using ADAS-Cog Items

Autor: Frederick A. Schmitt, Sibel Tekin, Kolbjørn Brønnick, Dag Aarsland, Xiangyi Meng, Jason T. Olin
Rok vydání: 2010
Předmět:
Zdroj: American Journal of Alzheimer's Disease & Other Dementiasr. 25:407-413
ISSN: 1938-2731
1533-3175
DOI: 10.1177/1533317510367486
Popis: Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for ADAS-cog item scores and for 3 cognitive domain scores. A total of 362 patients were randomized to 3 to 12 mg/d rivastigmine capsules and 179 to placebo. Patients with PDD receiving rivastigmine improved versus placebo on items: word recall, following commands, ideational praxis, remembering test instructions, and comprehension of spoken language (P < .05), with standardized mean differences ranging from 0.04 to 0.30. Rivastigmine also showed significant effects versus placebo on all domains: memory, language, and praxis. The ADAS-cog is sensitive to broad cognitive changes in PDD. Overall, rivastigmine was associated with improvements on individual cognitive items and general cognitive domains.
Databáze: OpenAIRE